|
SUMO1P3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.87429999590705E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.96289999990718E-07 |
| Normal-vs-Stage2 |
1.397870E-03 |
| Normal-vs-Stage3 |
5.07210000000313E-07 |
| Normal-vs-Stage4 |
6.03399996634835E-10 |
| Stage1-vs-Stage2 |
8.000200E-01 |
| Stage1-vs-Stage3 |
6.070200E-01 |
| Stage1-vs-Stage4 |
6.742600E-03 |
| Stage2-vs-Stage3 |
5.754600E-01 |
| Stage2-vs-Stage4 |
3.364000E-02 |
| Stage3-vs-Stage4 |
2.666100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.78259962346772E-10 |
| Normal-vs-AfricanAmerican |
2.347900E-02 |
| Normal-vs-Asian |
2.36180000001696E-06 |
| Caucasian-vs-AfricanAmerican |
7.169600E-02 |
| Caucasian-vs-Asian |
4.138000E-01 |
| AfricanAmerican-vs-Asian |
2.753200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.83279999960351E-08 |
| Normal-vs-Female |
4.81619999992411E-07 |
| Male-vs-Female |
1.595430E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.57169999979313E-07 |
| Normal-vs-Age(41-60Yrs) |
4.71190000017607E-07 |
| Normal-vs-Age(61-80Yrs) |
7.13609999980491E-07 |
| Normal-vs-Age(81-100Yrs) |
3.011900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.605800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.869200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.444000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.867000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.471000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.800800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.722000E-01 |
| Classical-VS-Follicular |
2.308600E-01 |
| Classical-VS-Other |
9.946600E-01 |
| Classical-VS-Normal |
2.44369999791161E-08 |
| Tall-VS-Follicular |
5.381700E-02 |
| Tall-VS-Other |
5.294800E-01 |
| Tall-VS-Normal |
6.73589999999891E-07 |
| Follicular-VS-Other |
7.043400E-01 |
| Follicular-VS-Normal |
1.422820E-03 |
| Other-VS-Normal |
2.341800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.93529999984399E-07 |
| Normal-vs-N1 |
1.63500000205374E-08 |
| N0-vs-N1 |
9.985600E-02 |
|
|
